Spyre Therapeutics to Participate in Upcoming September Investor Conferences

Spyre Therapeutics plans multiple September 2026 conference appearances with webcast access for investors and analysts.

Rhea-AI Summary

Spyre Therapeutics (SYRE)/b) will participate in three investor conferences in September 2026, including events hosted by Citi, Wells Fargo, and Stifel, featuring fireside chats on September 9, 10, and 23.Management will also hold one-on-one investor meetings, with live audio webcasts and replays available on Spyre’s investor events website.

Argus Sep 4 session

+1.98% close to close Open Argus

Details

News Market Reaction – SYRE

On Sep 4, the first trading day after this news, SYRE closed 1.98% above the previous close.

Data tracked by StockTitan Argus for the Sep 4 session.

Key Figures

Citi conference date: September 9, 2026 Citi fireside time: 10:00 am ET Wells Fargo conference date: September 10, 2026 +4 more

Citi conference date

September 9, 2026

Citi 2026 BioPharma Back to School Conference

Citi fireside time

10:00 am ET

September 9, 2026

Wells Fargo conference date

September 10, 2026

Wells Fargo 21st Annual Healthcare Conference

Wells Fargo fireside time

8:00 am ET

September 10, 2026

Stifel forum date

September 23, 2026

Stifel 2026 Virtual Immunology and Inflammation Forum

Stifel fireside time

8:30 am ET

September 23, 2026

Conference edition

21st Annual

Wells Fargo Healthcare Conference

Historical Context

5 past events · Latest: Aug 25

5 events

1. Aug 25

   RA clinical data

   24h Move

   -12.8%

   RA efficacy magnitude missed the company's internal monotherapy prioritization threshold

2. Aug 10

   HS trial initiation

   24h Move

   +0.4%

   SPY772 launched and the randomized Phase 2 SKYLIGHT trial began

3. Aug 07

   Inducement awards

   24h Move

   +0.4%

   Equity awards covering 19,436 options and 6,186 restricted stock units

4. Aug 04

   2Q26 earnings

   24h Move

   -0.6%

   Positive Phase 2 data and cash runway contrasted with a quarterly net loss

5. Jul 02

   Inducement awards

   24h Move

   +2.4%

   Equity awards included options covering 58,843 shares and 2,134 RSUs

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

α4β7, TL1A, IL-23, IL-17A/F

4 terms

α4β7 medical

"Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7"

A4β7 (alpha‑4 beta‑7) is a cell-surface protein called an integrin that acts like a molecular address label on certain white blood cells, helping them migrate specifically to gut tissue. It matters to investors because drugs that block or modify α4β7 can change how immune cells reach the gut, making it a key drug target in conditions such as inflammatory bowel disease; progress in clinical trials, approvals, or patent positions around α4β7-targeting therapies can affect a biotech or pharmaceutical company’s prospects.

TL1A medical

"extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F"

TL1A is a small signaling protein produced by the immune system that tells certain immune cells to ramp up inflammation, similar to a thermostat that raises the heat in response to a trigger. Investors watch TL1A because drugs or tests that block or measure it can change how inflammatory diseases are treated and diagnosed, affecting the commercial value of therapies, clinical trial outcomes, and potential regulatory approvals.

IL-23 medical

"extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F"

Interleukin-23 (IL-23) is a signaling protein the immune system uses to turn up inflammation, acting like a thermostat that raises immune activity. It matters to investors because drugs that block IL-23 can reduce harmful inflammation in conditions such as psoriasis and inflammatory bowel disease, creating large treatment markets and regulatory milestones; trial results, approvals, or patent news around IL-23 therapies can strongly affect company value.

IL-17A/F medical

"extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F"

IL-17A/F is a signaling protein produced by certain immune cells that combines elements of two related molecules (IL-17A and IL-17F) and helps trigger and amplify inflammation. It matters to investors because therapies that block or modulate IL-17A/F can reduce symptoms in autoimmune and inflammatory diseases, so clinical trial results, regulatory decisions, and safety signals for such drugs can significantly change a biotech or pharmaceutical company's market value—like repairing a faulty circuit that stabilizes a machine.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients, today announced that management will participate in the following upcoming investor conferences:

Event: Citi 2026 BioPharma Back to School Conference – New York
Date: Wednesday, September 9, 2026
Fireside Time: 10:00 am ET

Event: Wells Fargo 21st Annual Healthcare Conference – Boston
Date: Thursday, September 10, 2026
Fireside Time: 8:00 am ET

Event: Stifel 2026 Virtual Immunology and Inflammation Forum
Date: Wednesday, September 23, 2026
Fireside Time: 8:30 am ET

Members of the Spyre management team will also host one-on-one investor meetings during the conferences.

Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and a simpler treatment experience for patients. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F as well as rational combination programs.

For more information, visit Spyre's website at www.spyre.com.

For Investors:     
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
Eric.mcintyre@spyre.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Spyre Therapeutics (SYRE) present at the Citi 2026 BioPharma Back to School Conference?

Spyre Therapeutics will participate in the Citi 2026 BioPharma Back to School Conference in New York on Wednesday, September 9, 2026, with a fireside chat scheduled for 10:00 am ET.

What are the details of Spyre Therapeutics (SYRE) participation at the Wells Fargo 21st Annual Healthcare Conference?

Spyre Therapeutics will join the Wells Fargo 21st Annual Healthcare Conference in Boston on Thursday, September 10, 2026, with a fireside chat at 8:00 am ET.

When is Spyre Therapeutics (SYRE) presenting at the Stifel 2026 Virtual Immunology and Inflammation Forum?

The company will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Wednesday, September 23, 2026, with a fireside chat starting at 8:30 am ET.

Will Spyre Therapeutics (SYRE) hold one-on-one investor meetings during these September 2026 conferences?

Yes. Members of the Spyre Therapeutics management team plan to host one-on-one investor meetings during the Citi, Wells Fargo, and Stifel conferences.

How can investors access Spyre Therapeutics (SYRE) September 2026 conference webcasts?

Live audio webcasts and replays of Spyre Therapeutics’ conference appearances will be available on the company’s investor events website at https://ir.spyre.com/events-and-presentations.

What does Spyre Therapeutics focus on as a clinical-stage biotech company?

Spyre Therapeutics is a clinical-stage biotechnology company developing next-generation immunology therapies, including investigational extended half-life antibodies targeting α4β7, TL1A, IL-23, and IL-17A/F, along with rational combination programs.